2,038
Participants
Start Date
June 18, 2020
Primary Completion Date
October 12, 2021
Study Completion Date
October 12, 2021
VPM1002
The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
Placebo
The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
emovis GmbH, Berlin
Klinische Forschung Berlin GbR, Berlin
Klinische Forschung Hamburg GmbH, Hamburg
Klinische Forschung Hannover Mitte GmbH, Hanover
Medizinische Hochschule Hannover, Hanover
Medizentrum Essen Borbeck, Essen
BAG Dres. med. Quist PartG, Mainz
Studienzentrum Dr. Keller, Frankfurt am Main
Hautarztpraxis Dres. Leitz & Kollegen, Stuttgart
SocraTec R&D GmbH, Erfurt
MECS Cottbus GmbH, Cottbus
SIBAmed GmbH & Co. KG, Leipzig
Collaborators (1)
FGK Clinical Research GmbH
INDUSTRY
Serum Life Science Europe GmbH
INDUSTRY